InterAct Therapeutics, Inc.
PrivateLast Round
Seed Round
Jul 21, 2026
Momentum
Top 25%
of companies Caplight tracks
Company Overview
InterAct Therapeutics, Inc. is a biotechnology company that develops AAV-based gene therapies to treat metastatic cancer, with an initial focus on breast cancer liver metastasis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
InterAct Therapeutics, Inc. Comparables
Compare InterAct Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Vironexis Biotherapeutics | 79% | |
| Siren Biotechnology | 73% | |
| Incendia Therapeutics | 73% |
InterAct Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | Jul 21, 2026 | ||||
| Accelerator | Dec 11, 2025 |
InterAct Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Dais Partners | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 21, 2026
$250K raised in Seed Round.
- Feb 20, 2026
Grew 400% QoQ from 1 to 5 employees.
Recent news
Latest coverage and updates
- is_developingOct 5, 2026
InterActtx is developing IAT-S2, an AAV8-based gene therapy designed to modulate the liver microenvironment and suppress metastatic outgrowth in breast cancer liver metastases; the announcement was made in Indiana on Oct 5th '26.
- is_developingOct 5, 2026
As of Oct '26, InterActtx is developing IAT-S2 to address the tumor-liver microenvironment and is preparing IND-enabling studies with Genezen's support for toxicology, GMP manufacturing, and a planned Phase 1 trial.
InterAct Therapeutics, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about InterAct Therapeutics, Inc.'s valuation, stock price, and market status.
Is InterAct Therapeutics, Inc. a public or private company?
InterAct Therapeutics, Inc. is a private company.
What is the current stock price of InterAct Therapeutics, Inc.?
InterAct Therapeutics, Inc. is a private company, so its shares have no public market price. Caplight tracks InterAct Therapeutics, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is InterAct Therapeutics, Inc. worth (valuation)?
Valuation information for InterAct Therapeutics, Inc. is not publicly available.
Can I buy InterAct Therapeutics, Inc. stock?
InterAct Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was InterAct Therapeutics, Inc.'s last funding round?
InterAct Therapeutics, Inc.'s most recent funding round was Seed Round on July 21, 2026.
Who are the main investors in InterAct Therapeutics, Inc.?
Key investors in InterAct Therapeutics, Inc. include Dais Partners.
Will InterAct Therapeutics, Inc. IPO soon?
No public IPO plans have been announced for InterAct Therapeutics, Inc..
How can I track InterAct Therapeutics, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in InterAct Therapeutics, Inc.'s shares on secondary markets.